KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $3.1 billion.

  • Amgen's Cost of Revenue fell 688.82% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 billion, marking a year-over-year decrease of 532.74%. This contributed to the annual value of $12.9 billion for FY2024, which is 5214.77% up from last year.
  • As of Q3 2025, Amgen's Cost of Revenue stood at $3.1 billion, which was down 688.82% from $3.0 billion recorded in Q2 2025.
  • Over the past 5 years, Amgen's Cost of Revenue peaked at $3.3 billion during Q3 2024, and registered a low of $1.5 billion during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $1.8 billion (2023), whereas its average is $2.3 billion.
  • In the last 5 years, Amgen's Cost of Revenue tumbled by 775.81% in 2022 and then soared by 8604.65% in 2024.
  • Amgen's Cost of Revenue (Quarter) stood at $1.7 billion in 2021, then rose by 1.69% to $1.7 billion in 2022, then surged by 78.13% to $3.1 billion in 2023, then changed by 0.0% to $3.1 billion in 2024, then fell by 0.96% to $3.1 billion in 2025.
  • Its Cost of Revenue was $3.1 billion in Q3 2025, compared to $3.0 billion in Q2 2025 and $3.0 billion in Q1 2025.